Compare AbbVie Inc (ABBV) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Norfolk Southern Corporation — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Norfolk Southern Corporation trades at $319.48 (market cap $72.49B). The key difference: AbbVie Inc is far larger — about 6.2× Norfolk Southern Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NSC | |
|---|---|---|
Market Cap | $449.91B | $72.49B |
Sector | Health | Technology |
52-Week High | $261.07 | $325.68 |
52-Week Low | $184.85 | $259.49 |
Enterprise Value | $513.38B | $88.25B |
Dividend Yield | 2.72% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Norfolk Southern (NSC) trades at $321.9, down 0.25% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $337. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the ongoing merger process with Union Pacific, a key regulatory and operational focus.
The outlook for NSC is cautiously optimistic, with potential upside from the merger and consistent earnings performance, but risks include regulatory hurdles for the merger and rich valuation multiples. Investors should weigh the strong cash flow generation against execution risks in a consolidating industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
